Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor inhibitor · 1 trial · 1 indication
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Name | Type | Description |
|---|---|---|
| Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor | DRUG | - |
Inclusion Criteria: * Histologically documented RCC with metastases. * Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to disease progression or unacceptable treatment-related toxicity Exclusion Criteria: * Any prior systemic treatment for Renal Cell Carcinoma \[RC...
The VEGFR and PDGFR inhibitor is being studied for kidney neoplasms, specifically metastatic renal cell carcinoma. It is a small molecule oncology agent developed by Pfizer. One Phase 2 trial has evaluated it in patients with metastatic renal cell carcinoma, and that trial has been completed.
The agent targets vascular endothelial growth factor receptor, or VEGFR, and platelet-derived growth factor receptor, or PDGFR. It is an anti-angiogenesis small molecule that inhibits both receptor classes. Its Phase 2 trial in metastatic renal cell carcinoma was titled as an anti-angiogenesis agent study.
Pfizer, Inc. is the developer of the VEGFR and PDGFR inhibitor. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 2 study of the agent in metastatic renal cell carcinoma.
The VEGFR and PDGFR inhibitor is in Phase 2 development. Its single clinical trial, NCT00076011, was a Phase 2 study in metastatic renal cell carcinoma that has been completed. The agent is investigational and is not approved for use.
NCT00076011 is the Phase 2 trial of the VEGFR and PDGFR inhibitor. Titled Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma, it enrolled 52 patients aged 18 years and older across the United States, France, and Germany. The trial was uncontrolled, non-randomized, and has been completed.
Yes. AG-013736 is the investigational code name used for the VEGFR and PDGFR inhibitor in its Phase 2 trial, NCT00076011, which studied the agent in patients with metastatic renal cell carcinoma. The full descriptor, VEGFR and PDGFR inhibitor, and the code name AG-013736 refer to the same Pfizer compound.